Altimmune completes dosing in MOMENTUM trial to treat obesity

Altimmune has completed dosing the last subject in its Phase II MOMENTUM clinical trial of pemvidutide to treat obesity or overweight.

The placebo-controlled, randomised, multi-centre study is being carried out at nearly 30 sites in the US.